Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

Biosimilars Business Roundup: October 2023

November 1st 2023

By Skylar Jeremias

Between 3 regulatory approvals, 2 complete response letters, and new data and industry insights, October brought a number of business updates that have the potential to impact the entire US biosimilar industry.

Provider Acceptance Driving Confidence in Biosimilar Therapy

October 31st 2023

Providers speak to the importance of being knowledgeable of efficacy and safety data before prescribing biosimilars to patients.

Navigating Challenges Associated with Biosimilars Across Various Disease States

October 31st 2023

Clinical and social challenges associated with biosimilars are discussed by key opinion leaders.

Pegfilgrastim Biosimilar Proves Effective Against Neutropenia in Patients With Breast Cancer

October 31st 2023

By Skylar Jeremias

A recent study found that a pegfilgrastim biosimilar was effective against chemotherapy-induced neutropenia and had comparable safety and efficacy profiles compared with the originator (Neulasta) in patients with breast cancer.

Dr Ivo Abraham Column: Not All Quiet on the Biologics Front—Biosimilars, Biobetters, and Bioparallels

October 30th 2023

By Ivo Abraham, PhD

In his comeback column, Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, explores the world of biobetters and the complicated dynamics surrounding the FDA approval of Zymfentra, the first subcutaneous infliximab.

Dr Stephen Hanauer Gives Insight Into Growing US Adalimumab Market

October 29th 2023

By Skylar Jeremias

Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, reflects on data concerning the potential for adalimumab biosimilars to gain significant market share.

Commercial Biosimilar Coverage Is on the Rise, but Preferences Still Vary

October 28th 2023

By Skylar Jeremias

A poster from AMCP Nexus quantifies trends in biosimilar coverage within Tufts Medical Center, finding that payer coverage of these products has increased but individual preferences among payers still vary.

The Top 5 Biosimilar Articles for the Week of October 23

October 27th 2023

By Skylar Jeremias

Here are the top 5 biosimilar articles for the week of October 23, 2023.

AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry

October 26th 2023

By Skylar Jeremias

Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.

Eye on Pharma: New GI Data and Byooviz Interchangeability Propel Biosimilars Into the Future

October 25th 2023

By Skylar Jeremias

As Celltrion releases new data on its subcutaneous infliximab product in gastroenterology conditions, Samsung Bioepis secures an interchangeability designation for Byooviz, making it the second ranibizumab biosimilar to be deemed interchangeable with the reference product.